Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

NCT02962063 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

BIOLOGICAL: durvalumab
DRUG: carboplatin AUC 2/paclitaxel
RADIATION: External beam radiation (EBRT)
PROCEDURE: esophagogastrectomy
DRUG: Tremelimumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]